Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 9, Issue 1, Pages 39-46Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nmt-2018-0034
Keywords
dyskinesia; levodopa; Parkinson's disease; quality of life
Categories
Funding
- AbbVie Inc., North Chicago, IL, USA
- National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- Parkinson's UK
- PDNMG
- EU Horizon 2020
- IMI initiative
- UCB
- Britannia
- AbbVie
- GSK Pharmaceuticals
- Boehringer Ingelheim
- Neuronova
- Mundipharma
Ask authors/readers for more resources
Aim: To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden. Patients & methods: Post hoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and >= 4 h/day of levodopa-induced dyskinesia at baseline. Results & conclusions: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with >= 4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa-carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available